Veradermics, Incorporated saw its stock price surge approximately 40% on Monday, reaching $95.28 in early afternoon trading, after the company announced that its experimental oral hair-loss treatment, VDPHL01, successfully met all primary and key secondary endpoints in a Phase 2/3 clinical trial. The study, which enrolled 519 men with mild-to-moderate pattern hair loss, marks a significant step toward a potential FDA approval filing.
Clinical Trial Results
The double-blind, placebo-controlled study, designated Study '302,' evaluated VDPHL01 at two dosing regimens: 8.5 mg once daily and 8.5 mg twice daily, compared to a placebo. After six months, patients receiving the once-daily dose experienced an average increase of 30.3 hairs per square centimeter in the target area of the scalp, while those on the twice-daily regimen saw an average gain of 33.0 hairs per square centimeter. In contrast, the placebo group showed only a 7.3 hair increase per square centimeter.
Patient-reported outcomes further bolstered the results. According to Veradermics, 79.3% of participants on the once-daily regimen and 86.0% on the twice-daily regimen reported at least some improvement in hair coverage, compared to just 35.6% in the placebo group.
Safety Profile
Importantly, the six-month data revealed no treatment-related serious adverse events or heart-related adverse events of special interest, a critical consideration given that oral minoxidil was originally developed as a blood pressure medication. The most common side effects included peripheral edema and hypertrichosis, or excessive hair growth elsewhere on the body.
Market Context and Competition
Veradermics is positioning VDPHL01 as a potential first FDA-approved oral treatment for pattern hair loss in nearly three decades. The company estimates that approximately 50 million U.S. men and 80 million Americans overall are affected by this condition. Currently, the market is dominated by topical products like Rogaine, generic finasteride, and off-label oral minoxidil. Telehealth platforms such as Hims & Hers Health and Ro also offer hair-loss treatments, adding to the competitive landscape.
Cantor Fitzgerald analyst Prakhar Agrawal noted a "stronger" commercial case for VDPHL01 following the latest data, as reported by BioPharma Dive. However, the company still faces significant hurdles, including completing pivotal trials and securing regulatory approval from the FDA.
Company Strategy
Veradermics is developing an extended-release formulation of minoxidil, aiming to reduce cardiac risks associated with the immediate-release version. CEO Reid Waldman stated that the formulation produced "marked increases in hair growth" and is designed to lower the risk of heart-related side effects.
The company's stock, trading under the ticker MANE on the New York Stock Exchange, hit an intraday high of $101.59 before settling at $95.28, reflecting strong investor enthusiasm.
Next Steps
Veradermics plans to continue its clinical program. The second Phase 3 trial in men, Study '304,' is expected to deliver results in the second half of 2026. Additionally, Study '306,' targeting female pattern hair loss in a Phase 2/3 format, is currently recruiting participants.
Despite the positive data, risks remain. The company must navigate regulatory approval, potential competition from low-cost generics, and market acceptance. Veradermics has acknowledged these challenges in its SEC filings, including competition, side effects, and regulatory hurdles.
